Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Kopeny

Physician Assistant, Medical Arlington Heights, IL Physician Assistant

NPI 1053341743 CMS profile 10689557

216 S Arlington Heights Rd, Arlington Heights, IL 60005

Open in the dashboard

General payments

$8,527

370 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Kopeny of Arlington Heights, IL is reported in the CMS Open Payments database as having received $8,527 across 370 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $601 30
2024 General $811 42
2023 General $1,156 51
2022 General $3,378 101
2021 General $2,581 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Kopeny
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Erin Kopeny were reported at $601. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Erin Kopeny Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,581 $156 $41–$563 $132
2022 $3,378 $185 $55–$649 $149
2023 $1,156 $199 $58–$717 $160
2024 $811 $206 $62–$740 $164
2025 $601 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Myovant Sciences Inc. $1,500 12 payments
  2. AbbVie, Inc. $1,288 59 payments
  3. Mayne Pharma Inc. $511 21 payments
  4. Novo Nordisk Inc $497 21 payments
  5. Pfizer Inc. $471 24 payments
  6. Amneal Pharmaceuticals LLC $399 21 payments
  7. TherapeuticsMD, Inc. $382 37 payments
  8. Sumitomo Pharma America, Inc. $353 12 payments
  9. Organon LLC $272 12 payments
  10. Agile Therapeutics, Inc. $268 14 payments
  11. Other $2,586 137 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,331 366 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,162 1 payment
  3. Education $35 3 payments
Products named General payments · program years 2021–2025
  1. MYFEMBREE $590 18 payments
  2. ORIAHNN $514 16 payments
  3. PREMARIN $473 23 payments
  4. UNITHROID $399 21 payments
  5. ANNOVERA $382 37 payments
  6. IMVEXXY $365 35 payments
  7. NURTEC ODT $353 11 payments
  8. UBRELVY $315 18 payments
  9. Twirla $268 14 payments
  10. NEXPLANON $235 10 payments
  11. Other $4,579 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

342

Median for Physician Assistant: 241

Drug cost

$8,963

Median for Physician Assistant: $4,110

Branded share of claims

30.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 73 $3,784
Progesterone Progesterone, Micronized Brand 51 $1,819
Estradiol (Once Weekly) Estradiol Brand 17 $907
Metronidazole Generic 15 $520
Medroxyprogesterone Acetate Generic 13 $503
Levothyroxine Sodium Generic 66 $329
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $279
Rosuvastatin Calcium Generic 13 $272
Valacyclovir Valacyclovir Hcl Brand 13 $224
Alprazolam Generic 21 $127

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$23,858

Medicare's payments for the services billed

Medicare patients

179

Average age 70

Services billed

364

179 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 51%
Arthritis 49%
Osteoporosis 22%
Depression 20%
Diabetes 18%
Ischemic heart disease 11%
COPD 10%
Cancer 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $89
$89 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $71
  • PFIZER INC. $8
$78 — —
UNITHROID
  • Amneal Pharmaceuticals LLC $71
$71 — —
Veozah
  • Astellas Pharma US Inc $65
$65 — —
NURTEC ODT
  • PFIZER INC. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record